Scarica l'app Stockscreener
3.70
0.27%
-0.010
Dopo l'orario di chiusura:
3.72
0.02
+0.54%
Prime Medicine Inc Borsa (PRME) Ultime notizie
A gene-editing company sets three September conference appearances - Stock Titan
Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Prime Medicine (NASDAQ:PRME) Upgraded to Strong-Buy at Chardan Capital - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Price Down 4.7%What's Next? - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Up 6.3%Here's What Happened - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 6.9%Should You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Rating Increased to Strong-Buy at BMO Capital Markets - MarketBeat
Prime Medicine Company Profile & Introduction - Moomoo
Prime Medicine (NASDAQ:PRME) Shares Gap UpStill a Buy? - MarketBeat
PRIME MEDICINE, INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $9 - Bitget
PRME Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
Prime (PRME) Results Breakdown: The Available Earnings Metric Delivers a Beat for the Current Session; Investor Response: Shares Fall 3.79% on the DayConsensus Beat Rate - vinanet.vn
BMO initiates Prime Medicine stock with outperform rating By Investing.com - Investing.com Canada
Alphabet Inc. Takes Position in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Prime Medicine: Soon In The Clinic (NASDAQ:PRME) - Seeking Alpha
Prime Medicine, Inc. Stock 12‑Month Price Target Cut to $6.92, Implies 124% Upside - TradingView
Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright - MarketBeat
Prime Medicine: An Initial Prognosis (NASDAQ:PRME) - Seeking Alpha
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
Prime Medicine (NASDAQ:PRME) Trading Up 7.3%Still a Buy? - MarketBeat
Prime Medicine's (PRME) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Weekly Recap: Q2 loss/runway into 2027 and PM647 arbitration win, IND Q3 - TradingView
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Renaissance Technologies LLC Sells 408,120 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Prime Medicine stock surges after winning arbitration with Beam By Investing.com - Investing.com Nigeria
Prime Medicine (NASDAQ:PRME) Announces Earnings Results, Meets Estimates - MarketBeat
JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Prime Medicine, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Prime Medicine Q2 net loss narrows on lower expenses - TradingView
Prime Medicine, Inc. 2026: Revenue $11.04M, EPS ($0.24) — 10-Q Summary - TradingView
PRME: Regulatory advances and cost reductions position pipeline for key clinical milestones in 2027 - TradingView
FDA milestones and Beam ruling frame outlook for Prime Medicine (NASDAQ: PRME) - stocktitan.net
Prime Medicine reports Q2 2026 net loss $42.1M, cash $108.8M; IND/CTA clearances for PM577a - TradingView
BRIEF-Prime Medicine, Inc. Q2 EPS USD -0.24 - TradingView
Prime Medicine reports $42.1 million Q2 net loss as pipeline advances - Quiver Quantitative
Prime Medicine (PRME) Slides 3.3% as Gene Editing Sector Faces Renewed CautionRSI Overbought Alerts - vinanet.vn
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - Yahoo Finance
Redmile Group LLC Takes $5.54 Million Position in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine Inc (PRME) Cash Flow - TradingKey
Prime Medicine Inc (PRME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prime Medicine Inc (PRME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prime Medicine Inc (PRME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prime Medicine Market Sentiment - Benzinga España
Prime Medicine Inc (PRME) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PRME|Prime Medicine Inc|Price:3.015|Chg%:+0.065 - TradingKey
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Prime Medicine, Inc. (PRME) and Community Health (CYH) - The Globe and Mail
Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Price to earnings forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history - Yahoo Finance UK
Prime Medicine Buy Rating Reiterated as Pipeline Advances; $6 Price Target Maintained - TipRanks
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease - The Manila Times
Prime Medicine receives FDA clearance for Wilson disease therapy - Investing.com
Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm577a In H1069q-Mutated Wilson Disease - TradingView
Prime Medicine, Inc. (PRME) stock price, news, quote and history - Yahoo Finance Singapore
Prime Medicine receives FDA clearance for Wilson disease therapy By Investing.com - Investing.com Canada
Prime Medicine expects first-in-human Wilson trial in second half of 2026 - Stock Titan
Tracking Cathie Wood: Backing Prime Medicine and SpaceX, Sells Off AtaiBeckley, Shopify - Moomoo
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):